Results 101 to 110 of about 385,065 (234)

Strategies for Monitoring Serum Protein Degradation With an Antibody Array‐Based Technology

Journal of Clinical Laboratory Analysis, EarlyView.
This study analyzed the stability of 480 proteins in human serum samples collected from 10 healthy donors and incubated at room temperature for 0–48 h. Antibody array profiling revealed significant time‐dependent degradation of 201 proteins. Subsequent physicochemical and functional enrichment analyses demonstrated that the degraded proteins were ...
Yanlin Wang, Min Lang, Wei Huang, Siwei Zhu, Yingqing Mao, Shuhong Luo, Hua Dong, Ruo‐Pan Huang   +7 more
wiley   +1 more source

Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function

Journal of Experimental Medicine, 1994
Antigen-specific T cell activation requires the engagement of the T cell receptor (TCR) with antigen as well as the engagement of appropriate costimulatory molecules. The most extensively characterized pathway of costimulation has been that involving the
K. Hathcock, G. László, C. Pucillo, P. Linsley, R. Hodes   +4 more
semanticscholar   +1 more source

Nano Delivery Strategy Opens Effective Avenues for the Treatment of Colorectal Cancer

Medicine Bulletin, EarlyView.
ABSTRACT Colorectal cancer (CRC) presents significant therapeutic challenges because of chemoresistance, systemic toxicity, and the complexity of the tumor microenvironment (TME). Nanodrug delivery systems (NDDS) have emerged as versatile platforms capable of overcoming these limitations by enhancing tumor accumulation, improving pharmacokinetics, and ...
Qiurong Wei, Yunli Xu, Tianjiao Zhang, Shuyu Xu, Haonan Wang, Yuan Wang, Xinxin Xie, Xiaolong Liang   +7 more
wiley   +1 more source

A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions

BMC Medical Informatics and Decision Making, 2018
Background Monoclonal antibodies blocking the Cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor have revolutionized the field of anti-cancer therapy for the last few years.
Aravindhan Ganesan, Theinmozhi Arulraj, Tahir Choulli, Khaled H. Barakat   +3 more
doaj   +1 more source

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors [PDF]

, 2016
PURPOSE: Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune response through inhibition of T-cell checkpoints has led to durable clinical responses ...
Agar, Nathalie Y. R., Bi, Wenya Linda, Du, Ziming, Dunn, Gavin P, Dunn, Ian F, Fecci, Peter E, Freeman, Gordon J, Greenwald, Noah F, Kaiser, Ursula B, Laws, Edward R, Jr, Mei, Yu, Reardon, David A, Santagata, Sandro, Woodmansee, Whitney W   +13 more
core   +3 more sources

Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control

Medicinal Research Reviews, EarlyView.
ABSTRACT Respiratory syncytial virus (RSV) is a common virus that causes respiratory infections, posing a serious threat, particularly to infants, the elderly, and individuals with compromised immune systems. As the leading cause of lower respiratory tract infections (LRTIs) in infants, RSV is responsible for millions of cases worldwide each year.
Jie Shi, Xiya Huang, Chunjun Ye, Yishan Lu, Yanyan Liu, Yuquan Wei, Xiawei Wei   +6 more
wiley   +1 more source

Immunohistochemical Expression of Programmed Death Ligand-1 in Tumour Milieu of Oral Cancer

Annals of Abbasi Shaheed Hospital and Karachi Medical & Dental College, 2020
Objectives: To determine the immunohistochemical expression of PD-L1 in oral squamous cell carcinoma and to correlate it with clinicopathological parameters.
Moomal Aslam Khan, Serajuddaula Syed, Noor Ul Wahab, Saima Akram Butt   +3 more
doaj   +1 more source

CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics

Journal of Experimental Medicine, 1997
The structurally related T cell surface molecules CD28 and CTLA-4 interact with cell surface ligands CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells (APC) and modulate T cell antigen recognition. Preliminary reports have suggested that CD80 binds
P. A. van der Merwe, D. Bodian, S. Daenke, P. Linsley, S. J. Davis   +4 more
semanticscholar   +1 more source

A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy

Precision Radiation Oncology, EarlyView.
The combination of immune checkpoint inhibitors (ICIs) and radiotherapy synergistically enhances efficacy through an “antigen release‐immune activation” closed‐loop mechanism, significantly improving outcomes in solid tumors (e.g., lung cancer, melanoma).
Guiling Song, Lei Wang, Guopeng Zhao, Song Tan, Xin Liu, Xinghua Li   +5 more
wiley   +1 more source

Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells [PDF]

, 2001
The inducible costimulator receptor (ICOS) is a third member of the CD28 receptor family that regulates T cell activation and function. ICOS binds to a newly identified ligand on antigen presenting cells different from the CD152 ligands CD80 and CD86. We
Aicher, A, Clark, EA, Daemen, K, Hayden-Ledbetter, M, Irgang, M, Korner, I, Ledbetter, JA, Pezzutto, A, Richter, G, Westermann, J   +9 more
core